{
    "organizations": [],
    "uuid": "c988411bf25ede9eeeda9eed0994ae43c9dc427a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-verona-pharma-expects-to-report-to/brief-verona-pharma-expects-to-report-top-line-data-from-phase-2b-trial-of-nebulized-rpl554-early-in-q2-idUSASB0C5E1",
    "ord_in_thread": 0,
    "title": "Verona Pharma Expects To Report Top-Line Data From Phase 2b Trial Of Nebulized RPl554​ Early In Q2",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 13 (Reuters) - Verona Pharma Plc:\n* VERONA PHARMA PROVIDES CLINICAL DEVELOPMENT UPDATE * VERONA PHARMA PLC - ‍ANTICIPATES REPORTING TOP-LINE DATA FROM ITS PHASE 2B TRIAL EARLY IN Q2 OF 2018 FOR NEBULIZED RPL554​\n* VERONA PHARMA PLC - ‍ANTICIPATES REPORTING TOP-LINE DATA FROM ITS PHASE 2A TRIAL IN LATE Q1 OF 2018 FOR CLINICAL TRIAL OF RPL554 FOR CYSTIC FIBROSIS​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-13T20:48:00.000+02:00",
    "crawled": "2018-02-14T12:51:20.029+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "verona",
        "pharma",
        "plc",
        "verona",
        "pharma",
        "provides",
        "clinical",
        "development",
        "update",
        "verona",
        "pharma",
        "plc",
        "reporting",
        "data",
        "phase",
        "2b",
        "trial",
        "early",
        "q2",
        "nebulized",
        "verona",
        "pharma",
        "plc",
        "reporting",
        "data",
        "phase",
        "2a",
        "trial",
        "late",
        "q1",
        "clinical",
        "trial",
        "rpl554",
        "cystic",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}